VBI Vaccines Inc. announced that the UK Medicines and Healthcare Products Regulatory Agency (MHRA) has granted marketing authorization for PreHevbri™ [Hepatitis B vaccine (recombinant, adsorbed)] for active immunization against infection caused by all known subtypes of the hepatitis B virus (HBV) in adults. It can be expected that hepatitis D will also be prevented by immunization with PreHevbri as hepatitis D (caused by the delta agent) does not occur in the absence of hepatitis B infection.